SCHEMBL14616831

SCHEMBL14616831

COCCn1c(-c2cnc(-c3ccc4scnc4c3)[nH]2)nc2ccc(C)cc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RIPK2 O43353 1/20 0.47
▸ KDM4E B2RXH2 2/20 0.37
▸ RECQL P46063 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ CASR P41180 1/20 0.36
▸ PTGER4 P35408 3/20 0.35
▸ BRD4 O60885 4/20 0.35
▸ NPC1 O15118 2/20 0.35
▸ RAB9A P51151 2/20 0.35
▸ POLB P06746 1/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ SMPD3 Q9NY59 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ AAK1 Q2M2I8 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14616796 0.93 RIPK2 (0.53) RIPK2KDM4ERECQLHSD17B10HPGD
SCHEMBL14616800 0.91 RIPK2 (0.53) RIPK2KDM4ERECQLHSD17B10HPGD
SCHEMBL14616801 0.90 RIPK2 (0.49) RIPK2KDM4ERECQLHSD17B10HPGD
SCHEMBL14616794 0.86 RIPK2 (0.44) RIPK2KDM4ERECQLHSD17B10HPGD
SCHEMBL14616799 0.86 RIPK2 (0.51) RIPK2KDM4ERECQLHSD17B10HPGD
SCHEMBL14616792 0.86 RIPK2 (0.43) RIPK2KDM4ERECQLHSD17B10HPGD
SCHEMBL14616834 0.85 RIPK2 (0.44) RIPK2KDM4ERECQLHSD17B10ALDH1A1
SCHEMBL14616793 0.85 RIPK2 (0.44) RIPK2KDM4ERECQLHSD17B10HPGD
SCHEMBL14616797 0.84 RIPK2 (0.52) RIPK2KDM4ERECQLHSD17B10HPGD
SCHEMBL2554816 0.84 KDM4E (0.37) RIPK2KDM4ERECQLHSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-17 — — US disclosed
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS MAP3K19, MAP3K20, MAP3K3 RIPK2 255/4885KDM4E 764/4885RECQL 1347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback